Scroll Back to Top
Blog

Posterior segment ophthalmology clinical trials: Key considerations for retinal study delivery

Back-of-the-eye, or posterior segment, clinical trials operate within a highly specialized research environment. Programs in wet age-related macular degeneration, diabetic macular edema, geographic atrophy, diabetic retinopathy and inherited retinal disease can involve advanced imaging, complex treatment delivery and participants with meaningful visual impairment. These factors affect nearly every element of ophthalmology study planning, from site selection and recruitment to endpoint governance and retention.

Begin with the specialist network

Retinal clinical studies frequently require investigators with disease-specific knowledge, advanced imaging infrastructure and hands-on experience with specific treatment regimens. Retina specialists at high-volume practices are often already managing dense clinic schedules that include imaging, injections and, less frequently, laser procedures. Protocols that layer research visits with rigid imaging sequences onto that existing workload, without accounting for real clinic flow, tend to produce slower-than-projected enrollment, higher-than-expected data queries and assessments completed at the edge of the visit window.1

Feasibility assessment should therefore examine imaging capability, treatment experience and daily clinic capacity together, rather than treating them as separate checkboxes.

Design recruitment around trusted referral pathways, and expect exclusion

Conventional advertising plays a limited role in many retinal studies, where eligibility often depends on detailed imaging findings, treatment history or genetically defined disease subtypes. A retrospective analysis across 87 retinal clinical trials involving 962 patients found that 51.8% were classified as screen failures, with imaging findings and visual acuity criteria the leading causes of exclusion, accounting for 44.5% and 14.7% of failures respectively.2,3

Patient reported barriers add further complexity. In a survey of diabetic retinopathy patients, nearly 30% declined trial participation, and in simulated retinal trial scenarios 45.5% of participants viewed a four-to-five hour visit as too long while 50% viewed a 72-week trial duration as excessive, with anxiety about injections notably higher among those with no prior injection experience.2

These figures suggest that trial recruitment planning for retinal studies should build in realistic screen failure rates from the outset and invest early in relationships with retina specialists and patient advocacy groups who can support identification of eligible and willing participants.

Protect imaging and visual function endpoints

Posterior segment trials commonly rely on optical coherence tomography, fundus autofluorescence, fundus photography and best corrected visual acuity testing, often reviewed through centralized reading centers to maintain consistency across sites and instrument types. Even well-established metrics carry technical nuance. Published research on diabetic macular edema found that central subfield thickness values are not directly interchangeable across different instruments, requiring validated conversion equations to compare results reliably across a global trial. 4

Masking adds another layer of complexity that is less prominent in anterior segment work. Because treatment effects can sometimes be visible on retinal imaging, masking plans need to map specific risks, such as characteristic treatment related findings on imaging, to specific controls, including separation of treating and assessing personnel, standardized image acquisition and independent central review.5

Plan around patient and caregiver burden

Retinal trial participants are often older, may have coexisting health conditions and may depend on caregivers for transportation and appointment support. Qualitative research into geographic atrophy found that patients frequently modified daily routines, driving habits and even work schedules because of vision loss, while caregivers reported adjusting their own schedules and experiencing frustration at being unable to improve outcomes for the people they support.6

Broader research into recruiting and retaining older adults across six large multicenter trials identified impaired health status, comorbidities and long study duration as key barriers, and found that solutions such as additional recruitment sites, communication training for site staff, redesigned patient materials and reimbursement of travel costs were the most effective responses.7 These same principles apply directly to retinal studies, where visit frequency and travel demands are often higher than in other ophthalmology research.

 

Account for the added complexity of advanced therapies

The operational gap widens further with retinal gene therapies. These programs typically involve a single administration procedure delivered surgically into the eye, followed by long-term safety monitoring that can extend up to 15 years, and they require identifying small, genetically defined and often geographically dispersed patient populations who meet both clinical and genetic criteria.8

Match the operating model to the study

Retinal trials are not simply anterior segment studies with additional imaging steps. Their success depends on a coordinated system of specialist sites, referral relationships, standardized assessments, central review and thoughtful patient support. Sponsors who build these elements into study design from the outset, rather than adding them after enrollment slows, are better positioned to manage the operational realities of retinal research.

Learn more about how Fortrea can support your posterior segment study.

References

  1. Kleinman DM. Designing retina clinical trials that work for sponsors, investigators and patients. IUVO Clinical. Published June 23, 2026. Accessed October 21, 2026.https://iuvoclinical.com/blog/2026/06/23/designing-retina-clinical-trials-that-work-for-sponsors-investigators-and-patients/
  2. GCP ClinPlus. Patient recruitment and retention strategies in chronic ophthalmic clinical trials. Accessed October 21, 2026.https://www.gcpclinplus.com/patient-recruitment-and-retention-strategies-in-chronic-ophthalmic-clinical-trials.html
  3. Hasan N, Mehrotra K, Danzig CJ, et al. Screen failures in clinical trials in retina. Ophthalmol Retina. 2024;8(11):1093-1099.
  4. Sun JK, Josic K, Melia M, et al. Conversion of central subfield thickness measurements of diabetic macular edema across Cirrus and Spectralis optical coherence tomography instruments. Trans Vis Sci Technol. 2021;10(14):34. doi:10.1167/tvst.10.14.34
  5. Clinical Trials 101. Blinding/masking and unblinding plans: building and protecting the blind in clinical trials. Accessed October 21, 2026.https://www.clinicaltrials101.com/blinding-masking-unblinding-plans-building-and-protecting-the-blind-in-clinical-trials-2/
  6. Singh RP, Patel SS, Nielsen JS, Schmier JK, Rajput Y. Patient-, caregiver-, and eye care professional-reported burden of geographic atrophy secondary to age-related macular degeneration. Am J Ophthalmic Clin Trials. 2019;2(1):1-6. doi:10.25259/AJOCT-9-2018.
  7. Buttgereit T, Palmowski A, Forsat N, et al. Barriers and potential solutions in the recruitment and retention of older patients in clinical trials. Age Ageing. 2021;50(6):1988-1996. doi:10.1093/ageing/afab172
  8. Medpace. Advancing gene therapy innovation in ophthalmology trials. Published June 4, 2026. Accessed October 21, 2026.https://www.medpace.com/blog/advancing-gene-therapy-innovation-in-ophthalmology-trials/

Choose how you like to connect.

We've been driving innovation with our tailored clinical solutions for 30+ years. Let's connect.

Write to us
Book a Meeting

Prefer to send an inquiry?

Tell us about your needs and our team will follow up shortly.

Service Interest(s) *
(Word, PDF, PPT, Excel, Image)
One file only.
60 MB limit.
Allowed types: gif jpg jpeg png bmp txt rtf html pdf doc docx ppt pptx xls xlsx xml.
Name

I agree to be contacted about products and services and receive other communications from Fortrea Inc. Please review Fortrea's Privacy Policy for further information. By submitting below, you consent to allow Fortrea Inc to store and process the personal information submitted above to provide you the content requested.

By clicking submit below, you consent to allow Fortrea Inc to store and process the personal information submitted above to provide you the content requested.

Schedule a time with a Fortrea Specialist

Connect with our team to discuss your needs and explore the right solutions for your clinical development goals — quick, clear, and hassle‑free.